Phase II study of capecitabine and temozolomide (CAPTEM)in patients with unresectable neuroendocrien tumor
Not Applicable
- Conditions
- gastroenteropancreatic neuroendocrine tumor
- Registration Number
- JPRN-UMIN000024091
- Lead Sponsor
- yokohama city university hospital oncology division
- Brief Summary
undisclosed
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 35
Inclusion Criteria
Not provided
Exclusion Criteria
Hb < 8.0g/dl WBC <3000 Neutrocyte <1500 Plt <100000 severe liver or renal disease T-bil> 3ULN Alb <3.0g/dl AST> 5 X ULN ALT> 5 X ULN brain metastasis severe bone metastasis uncontrolable DM severe heart disease
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Overall response rate
- Secondary Outcome Measures
Name Time Method Time to treatment failure Progression-free survival Overall survival